RJS Biologics L.L.C.

Biotech · Defunct

Small-molecule drug delivery system that uses cancer-cell-produced inflammatory proteins to selectively transport imaging agents and chemotherapeutics into tumor cells

Grants
$225K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Rationally-designed, modular imaging agents for the targeted detection of tumors.$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2204ArCHitect Therapeutics——
2205SHAL TECHNOLOGIES, INC.——
2206Cognosetta, Inc.——
2207RJS Biologics L.L.C.——
2208TRAVERSE BIOSCIENCES, INC.——
2209ARIETIS CORPORATION——
2210MBX Biosciences—$95M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.